Make your money go further for just 25p per day

IS Pharma : Variquel® approval and management continues to shine

23/11/2009 · IS Pharma (ISPH) 

IS Pharma (LSE: ISPH), the international speciality pharmaceutical company, and a real star EIS qualifying issue from 2007 continues to deliver.

Today the group announced that marketing authorizations (‘MAs’) for Variquel,a key product for the group, have now been received for all of the major European markets.

IS Pharma acquired Variquel in April 2008 when it was marketed only in Germany, Austria and Switzerland. They have since successfully completed the European Mutual Recognition Procedure and subsequently obtained the abovementioned MAs, which has enabled IS Pharma to launch Variquel in the UK, France,…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More on IS Pharma

IS Pharma plc – placing at a premium gives confidence and we get a dividend as well

06/10/2010 · Company Insights
The speciality pharmaceutical company has announced that it has raised £3.6m at 77p per share with…

IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme

02/06/2010 · Company Insights
The company, which provides specialist pharmaceuticals and equipment in core areas such as Oncology and Neurology…

More Company Insights

Bonkers Bargains: another upgrade and still a bargain

12/11/2024 · Time Finance

AIM new arrivals and departures October 2024

08/11/2024 · GenIP · Pulsar Helium

Sign-up to our free email updates

SIGN UP